by Victoria Langowska | Jul 23, 2025 | Uncategorized
CHICAGO — In this video, Sham Mailankody, MBBS, highlights data from a study of carfilzomib, lenalidomide and dexamethasone, with or without daratumumab, for patients with newly diagnosed multiple myeloma.“Four drugs appear to be better than three drugs, even in the...
by Victoria Langowska | Jul 23, 2025 | Uncategorized
CHICAGO — In this video, Sham Mailankody, MBBS, discusses results from the long-term follow-up of CARTITUDE-1 patients receiving ciltacabtagene autoleucel, or cilta-cel, for the treatment of relapsed or refractory multiple myeloma.“A third of the patients were...
by MM360 Staff | Jul 19, 2025 | Uncategorized
Source: CureToday articles The FDA’s Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple myeloma patient population. Read More
by Matthew Shinkle | Jul 18, 2025 | Uncategorized
An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used in the proposed dosages for previously treated adult patients with relapsed/refractory multiple myeloma.The FDA Oncologic Drugs Advisory...
by MM360 Staff | Jul 17, 2025 | Uncategorized
Source: CureToday articles Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how incidental back pain led to an unexpected cancer diagnosis, the initial shock and fear that followed, and the pivotal...
by MM360 Staff | Jul 17, 2025 | Uncategorized
Source: CureToday articles Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving clinical data—highlighting the shift toward a comprehensive, multi-phase approach that begins with a four-drug induction...
